Hexokinase‐2 as a Therapeutic Target: Alleviating Herpes Simplex Keratitis Through Metabolic Reprogramming
Advanced Science · 2025
DOI: 10.1002/advs.202503690 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Dan Jiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, 325000, China. Hauptthemen laut MEDLINE: Hexokinase, Keratitis, Herpetic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Program of Zhejiang Province, National Natural Science Foundation of China, Joint Research Program of Eye Research Center.
Abstract (Originalsprache)
Herpes simplex keratitis (HSK) is a leading infectious cause of blindness worldwide, with current therapies primarily targeting viral replication rather than addressing host‐cell injury. RNA sequencing of corneal tissue from HSK patients and healthy donors identifies a metabolic shift from mitochondrial oxidative phosphorylation to aerobic glycolysis. Notably, hexokinase‐2 (HK2), a pivotal glycolytic enzyme, exhibits the greatest up‐regulation, coinciding with a marked reduction in the activity of mitochondrial respiratory chain complexes in HSK corneas. Pharmacological inhibition of HK2 with lonidamine in human corneal epithelial cells reduces herpes simplex virus type 1 (HSV‐1) replication while preserving cell viability. In a murine model of HSK, topical lonidamine restored respiratory‐chain activity, lowered viral load, and accelerated corneal re‐epithelialization; its early therapeutic efficacy surpassed that of ganciclovir, and combination therapy conferred additive benefit. These findings identify HK2‐driven glycolytic reprogramming as a pathogenic hallmark of HSK and demonstrate that metabolic targeting concurrently restricts viral propagation and promotes tissue regeneration. Thus, metabolic intervention has the potential to complement direct antiviral therapy and represents a promising, clinically translatable strategy to preserve vision in HSK.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, 325000, China.
- State Key Laboratory of Ophthalmology, Optometry and Visual Science, Eye Hospital, Wenzhou Medical University, Wenzhou, 325000, China.
- Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, 200000, China.
- State Key Laboratory of Medical Genomics, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200000, China.
- Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310000, China.
ORCID-Profile: Wei Chen
Förderung
- Key Research and Development Program of Zhejiang Province
- National Natural Science Foundation of China
- Joint Research Program of Eye Research Center
Zitieren
APA
Jiang, D., Sun, Y., Yu, X., Wang, R., Zhang, Y., Yu, J., Xie, S., Cai, Y., Luo, Y., & Chen, W. (2025). Hexokinase‐2 as a Therapeutic Target: Alleviating Herpes Simplex Keratitis Through Metabolic Reprogramming. Advanced Science. https://doi.org/10.1002/advs.202503690
Vancouver
Jiang D, Sun Y, Yu X, Wang R, Zhang Y, Yu J, et al. Hexokinase‐2 as a Therapeutic Target: Alleviating Herpes Simplex Keratitis Through Metabolic Reprogramming. Advanced Science. 2025. doi:10.1002/advs.202503690
BibTeX
@article{Jiang2025,
author = {Jiang, Dan and Sun, Yining and Yu, Xintong and Wang, Ruoqi and Zhang, Yuting and Yu, Jinjie and Xie, Shuang and Cai, Yujia and Luo, Yuhong and Chen, Wei},
title = {Hexokinase‐2 as a Therapeutic Target: Alleviating Herpes Simplex Keratitis Through Metabolic Reprogramming},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202503690}
}
EUVIMED